HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present at three upcoming investor conferences in September.
Conference Details:
Event: H.C. Wainwright 26th Annual Global Investment Conference
Details: Presenting on Wednesday, September 11, 2024, at 11:30 a.m. ET and hosting investor meetings in New York, NY.
Event: Stifel Immunology and Inflammation Virtual Summit
Details: Presenting on Tuesday, September 17, 2024, at 12:00 p.m. ET and hosting virtual investor meetings.
Event: Cantor Global Healthcare Conference
Details: Presenting on Tuesday, September 17, 2024, at 2:30 p.m. ET and hosting investor meetings in New York, NY.
Links for live webcasts and replays, if available, will be posted on the News & Events page in the Investors & Media section of the Zura Bio website. Presentations will be archived on the website for at least 30 days following the event.
ABOUT ZURA BIO
Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.
